Epilepsy therapy beyond neurons: Unveiling astrocytes as cellular targets
Open Access
- 13 January 2025
- journal article
- Published by Wolters Kluwer Health in Neural Regeneration Research
- Vol. 21 (1) , 23-38
Abstract
Epilepsy is a leading cause of disability and mortality worldwide. However, despite the availability of more than 20 antiseizure medications, more than one-third of patients continue to experience seizures. Given the urgent need to explore new treatment strategies for epilepsy, recent research has highlighted the potential of targeting gliosis, metabolic disturbances, and neural circuit abnormalities as therapeutic strategies. Astrocytes, the largest group of nonneuronal cells in the central nervous system, play several crucial roles in maintaining ionic and energy metabolic homeostasis in neurons, regulating neurotransmitter levels, and modulating synaptic plasticity. This article briefly reviews the critical role of astrocytes in maintaining balance within the central nervous system. Building on previous research, we discuss how astrocyte dysfunction contributes to the onset and progression of epilepsy through four key aspects: the imbalance between excitatory and inhibitory neuronal signaling, dysregulation of metabolic homeostasis in the neuronal microenvironment, neuroinflammation, and the formation of abnormal neural circuits. We summarize relevant basic research conducted over the past 5 years that has focused on modulating astrocytes as a therapeutic approach for epilepsy. We categorize the therapeutic targets proposed by these studies into four areas: restoration of the excitation–inhibition balance, reestablishment of metabolic homeostasis, modulation of immune and inflammatory responses, and reconstruction of abnormal neural circuits. These targets correspond to the pathophysiological mechanisms by which astrocytes contribute to epilepsy. Additionally, we need to consider the potential challenges and limitations of translating these identified therapeutic targets into clinical treatments. These limitations arise from interspecies differences between humans and animal models, as well as the complex comorbidities associated with epilepsy in humans. We also highlight valuable future research directions worth exploring in the treatment of epilepsy and the regulation of astrocytes, such as gene therapy and imaging strategies. The findings presented in this review may help open new therapeutic avenues for patients with drug-resistant epilepsy and for those suffering from other central nervous system disorders associated with astrocytic dysfunction.Keywords
This publication has 225 references indexed in Scilit:
- Neural tissue engineering: From bioactive scaffolds and in situ monitoring to regenerationExploration, 2022
- Blocking TNFα‐driven astrocyte purinergic signaling restores normal synaptic activity during epileptogenesisGlia, 2018
- Treatment Outcomes in Patients With Newly Diagnosed Epilepsy Treated With Established and New Antiepileptic DrugsJAMA Neurology, 2018
- miR147b:Anovel key regulator of interleukin 1 beta‐mediated inflammation in human astrocytesGlia, 2018
- Epilepsy and astrocyte energy metabolismGlia, 2017
- P2Y1receptor inhibits GABA transport through a calcium signalling-dependent mechanism in rat cortical astrocytesGlia, 2014
- Astrocyte dysfunction in temporal lobe epilepsy: K+ channels and gap junction couplingGlia, 2012
- Adenosine dysfunction in epilepsyGlia, 2011
- Blockade of IL‐15 activity inhibits microglial activation through the NFκB, p38, and ERK1/2 pathways, reducing cytokine and chemokine releaseGlia, 2009
- Angiotensin receptor‐like immunoreactivity in adult brain white matter astrocytes and oligodendrocytesGlia, 2001